Literature DB >> 16214216

Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin.

Ann Van de Moere1, Sukhpal S Sandhu, Rajeev Kak, Keith W Mitchell, Stephen J Talks.   

Abstract

OBJECTIVE: To assess if posterior juxtascleral application of 40 mg triamcinolone acetonide (TA), given at the same time as initial photodynamic therapy (PDT) for predominantly classic choroidal neovascularization (CNV) related to age-related macular degeneration affects lesion growth at 3 and 6 months.
DESIGN: Comparative (nonrandomized) interventional study. PARTICIPANTS: The study group consists of 38 eyes of 38 patients. The control group consists of 73 eyes of 73 patients.
METHODS: Comparison of 2 consecutive case series collected at different times. The study group had a posterior juxtascleral TA with their initial PDT treatment. The controls were treated with PDT alone. All patients were reviewed at 1, 3, and 6 months. MAIN OUTCOME MEASURES: Change in total lesion size; secondary outcomes: area of leak, best-corrected visual acuity, number of treatments, and intraocular pressure.
RESULTS: There was significantly less growth of total lesion at 3 months (mean difference = 2.47 mm2; 95% confidence interval (CI): +1.22 to +3.72 mm2; P = 0.0002) and 6 months (mean difference = 2.88 mm2; 95% CI: +0.61 to +5.15 mm2; P = 0.0134) in patients given TA with PDT compared with PDT alone. There was also a significantly smaller residual area of leak at 3 months in the study group (mean difference = 1.07 mm2; 95% CI: +0.16 to +1.97 mm2; P = 0.02). At 6 months, the residual area of leak between the 2 groups became comparable (mean difference = 0.13 mm2; 95% CI = -1.59 to +1.33 mm2; P = 0.86). Mean number of letters lost on the logarithm of the minimum angle of resolution chart at 6 months was 9.1 letters (standard error of the mean [SEM] = 2.21) in the study group compared with 12.4 letters (SEM = 1.91) in the control group (P = 0.30). At 6 months, 10 of 36 eyes (27.8%) in the study group showed > or =15 letters loss, compared with 29 of 73 eyes (39.7%) in the control group. Intraocular pressure was raised in 4 of 38 eyes (10.5%). Fewer retreatments were required in the TA with PDT group (2.03 compared with 2.47 [P = 0.006]).
CONCLUSIONS: Posterior juxtascleral placement of TA with PDT at baseline significantly reduces CNV growth at 3 and 6 months. Fewer retreatments were required. Visual outcome may be improved, although we did not show a statistically significant improvement with this sample size. A larger, randomized trial with longer follow-up is justified.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16214216     DOI: 10.1016/j.ophtha.2005.06.018

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  10 in total

1.  Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab.

Authors:  Kohei Ishikawa; Hiroaki Nishihara; Shinsuke Ozawa; Chang-Hua Piao; Yasuki Ito; Mineo Kondo; Hiroko Terasaki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-10-31       Impact factor: 3.117

2.  Combination photodynamic therapy and juxtascleral triamcinolone acetonide for the treatment of a peripapillary choroidal neovascular membrane associated with papilloedema.

Authors:  A Tewari; G K Shah; M S Dhalla; J B Shepherd
Journal:  Br J Ophthalmol       Date:  2006-10       Impact factor: 4.638

3.  One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation.

Authors:  Yukari Shirakata; Chieko Shiragami; Ayana Yamashita; Eri Nitta; Atsushi Fujiwara; Fumio Shiraga
Journal:  Jpn J Ophthalmol       Date:  2012-09-19       Impact factor: 2.447

4.  Effect of photodynamic therapy with posterior sub-tenon triamcinolone acetonide on predominantly classic choroidal neovascularization: one-year results.

Authors:  Ayzin Deniz Sertoz; Orhan Ates; Sadullah Keles; Ibrahim Kocer; Destan Nil Kulacoglu; Orhan Baykal
Journal:  Eurasian J Med       Date:  2008-12

Review 5.  Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration.

Authors:  Arthur Geltzer; Angela Turalba; Satyanarayana S Vedula
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

6.  Effect of posterior juxtascleral triamcinolone acetonide on the efficacy and choriocapillaris hypoperfusion of photodynamic therapy.

Authors:  Aya Iriyama; Ryo Obata; Yuji Inoue; Hidenori Takahashi; Yasuhiro Tamaki; Yasuo Yanagi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-09-06       Impact factor: 3.117

7.  Subretinal injection of preservative-free triamcinolone acetonide and supernatant vehicle in rabbits: an electron microscopy study.

Authors:  Maurício Maia; Fernando Marcondes Penha; Michel Eid Farah; Eduardo Dib; André Príncipe; Acácio A S Lima Filho; Octaviano Magalhães; Edna Freymüller; Eduardo B Rodrigues
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-12-11       Impact factor: 3.117

8.  Combination therapy for choroidal neovascularisation.

Authors:  Albert J Augustin; Indre Offermann
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

9.  Effect of combined treatment with sub-Tenon injection of triamcinolone acetonide and photodynamic therapy in Japanese patients with age-related macular degeneration.

Authors:  Koko Saito; Teiko Yamamoto; Daijiro Tsuchiya; Ryo Kawasaki; Shion Haneda; Hidetoshi Yamashita
Journal:  Jpn J Ophthalmol       Date:  2009-10-22       Impact factor: 2.447

Review 10.  Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration.

Authors:  A Geltzer; A Turalba; S S Vedula
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.